Geographic Patterns of Carbapenem-Resistant Pseudomonas Aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 Nov 22

PMID 34807753

Citations 22

Authors

Yu-Lin Lee

Wen-Chien Ko

Po-Ren Hsueh

Affiliations

Soon will be listed here.

Abstract

Pseudomonas aeruginosa is a common pathogen that is associated with multidrug-resistant (MDR) and carbapenem-resistant (CR) phenotypes; therefore, we investigated its resistance patterns and mechanisms by using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program in the Asia-Pacific region from 2015 to 2019. MICs were determined using the broth microdilution method. Genes encoding major extended-spectrum β-lactamases and carbapenemases were investigated by multiplex PCR assays. Susceptibility was interpreted using the Clinical and Laboratory Standards Institute (CLSI) breakpoints. A total of 6,349 P. aeruginosa isolates were collected in the ATLAS program between 2015 and 2019 from 14 countries. According to the CLSI definitions, the numbers (and rates) of CR and MDR P. aeruginosa isolates were 1,198 (18.9%) and 1,303 (20.5%), respectively. For 747 of the CR P. aeruginosa strains that were available for gene screening, 253 β-lactamase genes were detected in 245 (32.8%) isolates. The most common gene was (29.0%, 71/245), followed by (24.9%, 61/245) and (20.8%, 51/245). The resistance patterns and associated genes varied significantly between the countries in the Asia-Pacific region. India had the highest rates of carbapenem resistance (29.3%, 154/525) and gene detection (17.7%, 93/525). Compared to those harboring either class A or B β-lactamase genes, the CR P. aeruginosa isolates without detected β-lactamase genes had lower MICs for most of the antimicrobial agents, including ceftazidime-avibactam and ceftolozane-tazobactam. In conclusion, MDR and CR P. aeruginosa infections pose a major threat, particularly those with detected carbapenemase genes. Continuous surveillance is important for improving antimicrobial stewardship and antibiotic prescriptions.

Citing Articles

Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.

Vidal-Cortes P, Campos-Fernandez S, Cuenca-Fito E, Del Rio-Carbajo L, Fernandez-Ugidos P, Lopez-Ciudad V Antibiotics (Basel). 2025; 14(2).

PMID: 40001421 PMC: 11851922. DOI: 10.3390/antibiotics14020178.

Risk Factors and Outcomes of Multidrug-resistant in Kelantan, Malaysia: A Multicenter Case-control Study.

Salim S, Din N, Rashid R, Hitam S, Deris Z Saudi J Med Med Sci. 2025; 13(1):18-25.

PMID: 39935999 PMC: 11809758. DOI: 10.4103/sjmms.sjmms_429_24.

β-Lactamase diversity in .

Mack A, Hujer A, Mojica M, Taracila M, Feldgarden M, Haft D Antimicrob Agents Chemother. 2025; 69(3):e0078524.

PMID: 39927781 PMC: 11881563. DOI: 10.1128/aac.00785-24.

Risk of Colonization with Multidrug-Resistant Gram-Negative Bacteria Among Travellers and Migrants: A Narrative Review.

Mendes Pedro D, Santos D, Meneses M, Goncalves F, Domingos G, Caneiras C Trop Med Infect Dis. 2025; 10(1).

PMID: 39852677 PMC: 11769174. DOI: 10.3390/tropicalmed10010026.

Surveillance of carbapenem resistance in Asian countries: a systematic review and meta-analysis.

Jayathilaka N, Denagamagei S, Nakkawita D, Senaratne T BMJ Open. 2024; 14(11):e088597.

PMID: 39551598 PMC: 11574409. DOI: 10.1136/bmjopen-2024-088597.

References

Karlowsky J, Kazmierczak K, Bouchillon S, de Jonge B, Stone G, Sahm D . Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2018; 62(7). PMC: 6021687. DOI: 10.1128/AAC.02569-17. View

Juan C, Zamorano L, Mena A, Alberti S, Perez J, Oliver A . Metallo-beta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J Antimicrob Chemother. 2010; 65(3):474-8. DOI: 10.1093/jac/dkp491. View

Li S, Jia X, Li C, Zou H, Liu H, Guo Y . Carbapenem-resistant and cephalosporin-susceptible : a notable phenotype in patients with bacteremia. Infect Drug Resist. 2018; 11:1225-1235. PMC: 6108401. DOI: 10.2147/IDR.S174876. View

Wang Y, Wang J, Wang R, Cai Y . Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2019; 22:18-27. DOI: 10.1016/j.jgar.2019.12.009. View

Spalding Walters M, Grass J, Bulens S, Hancock E, Phipps E, Muleta D . Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015. Emerg Infect Dis. 2019; 25(7):1281-1288. PMC: 6590762. DOI: 10.3201/eid2507.181200. View

Mombini S, Rezatofighi S, Kiyani L, Motamedi H . Diversity and metallo-β-lactamase-producing genes in Pseudomonas aeruginosa strains isolated from filters of household water treatment systems. J Environ Manage. 2018; 231:413-418. DOI: 10.1016/j.jenvman.2018.10.068. View

Kim M, Bae I, Jeong S, Kim S, Song J, Choi J . Dissemination of metallo-β-lactamase-producing Pseudomonas aeruginosa of sequence type 235 in Asian countries. J Antimicrob Chemother. 2013; 68(12):2820-4. DOI: 10.1093/jac/dkt269. View

Stone G, Smayevsky J, Kazmierczak K . Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012-2016. Diagn Microbiol Infect Dis. 2019; 96(1):114835. DOI: 10.1016/j.diagmicrobio.2019.05.007. View

Elabbadi A, Pont S, Verdet C, Plesiat P, Cretin F, Voiriot G . An unusual community-acquired invasive and multi systemic infection due to ExoU-harboring Pseudomonas aeruginosa strain: Clinical disease and microbiological characteristics. J Microbiol Immunol Infect. 2019; 53(4):647-651. DOI: 10.1016/j.jmii.2019.06.008. View

10.

Watanabe M, Iyobe S, Inoue M, Mitsuhashi S . Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991; 35(1):147-51. PMC: 244956. DOI: 10.1128/AAC.35.1.147. View

11.

Viasus D, Puerta-Alcalde P, Cardozo C, Suarez-Lledo M, Rodriguez-Nunez O, Morata L . Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin Microbiol Infect. 2019; 26(3):345-350. DOI: 10.1016/j.cmi.2019.07.002. View

12.

Schafer E, Malecki M, Tellez-Castillo C, Pfennigwerth N, Marlinghaus L, Higgins P . Molecular surveillance of carbapenemase-producing at three medical centres in Cologne, Germany. Antimicrob Resist Infect Control. 2020; 8:208. PMC: 6937969. DOI: 10.1186/s13756-019-0665-5. View

13.

Kresken M, Korber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann S, Seifert H . Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int J Antimicrob Agents. 2020; 55(6):105959. DOI: 10.1016/j.ijantimicag.2020.105959. View

14.

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P..... Clin Infect Dis. 2020; 72(7):e169-e183. DOI: 10.1093/cid/ciaa1478. View

15.

Rossolini G, Bochenska M, Fumagalli L, Dowzicky M . Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008-2018. Diagn Microbiol Infect Dis. 2021; 101(4):115512. DOI: 10.1016/j.diagmicrobio.2021.115512. View

16.

Liu W, Shih M, Chuang Y, Wang J, Sheng W . Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia. J Microbiol Immunol Infect. 2019; 52(5):788-795. DOI: 10.1016/j.jmii.2019.04.008. View

17.

Liu P, Ko W, Lee W, Lu P, Chen Y, Cheng S . In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from.... J Microbiol Immunol Infect. 2021; 55(5):888-895. DOI: 10.1016/j.jmii.2021.08.012. View

18.

Zhang Y, Zhou H, Jiang Q, Wang Q, Li S, Huang Y . Bronchoscope-related Pseudomonas aeruginosa pseudo-outbreak attributed to contaminated rinse water. Am J Infect Control. 2019; 48(1):26-32. DOI: 10.1016/j.ajic.2019.06.013. View

19.

Wong D, van Duin D . Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. Drugs. 2017; 77(6):615-628. PMC: 5473160. DOI: 10.1007/s40265-017-0725-1. View

20.

Ko W, Stone G . In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ann Clin Microbiol Antimicrob. 2020; 19(1):14. PMC: 7110689. DOI: 10.1186/s12941-020-00355-1. View